ArticleFrontiers in pharmacology2024

Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023.

Jinger Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.